Psoriasis is a chronic, inflammatory multisystem disease that affects up to 3.2% of the US
population. This guideline addresses important clinical questions that arise in psoriasis …

Psoriasis is a chronic, inflammatory, immune-mediated skin condition that affects 3 to 4% of
the adult US population, characterized by well-demarcated, erythematous plaques with …

Background Secukinumab, a fully human monoclonal antibody that selectively neutralizes IL‐
17A, has been shown to have significant efficacy and a favourable safety profile in the …

Background Drug survival is a marker for treatment sustainability in chronic diseases such
as psoriasis. Objective The aim of these analyses was to assess survival of biologic …

Interleukin (IL)–36α, IL-36β, and IL-36γ are innate mediators of acute epithelial
inflammation. We sought to demonstrate that these cytokines are also required for the …

Little is known about the drug survival of second-line biologic therapies for psoriasis in
routine clinical practice. We assessed drug survival of second-line biologic therapies and …

Real‐world evidence (RWE) meta‐analyses provide valuable insights from patients in
routine clinical practice. Secukinumab, the first fully human monoclonal antibody that …

Ustekinumab [UST] therapy during pregnancy has not yet been extensively evaluated in
patients with Crohn's disease. Here, we present the case of a 24-year-old woman with …

Importance There is a need for better understanding of the comparative safety of systemic
medications used in the treatment of psoriasis. Objective To compare the risk of serious …

Generalized pustular psoriasis (GPP) is a rare yet severe variant of psoriasis, characterized
by the eruption of superficial sterile pustules that appear suddenly and widely distributed …